$CNSP

Fisher Michal purchased $10K of CNSP

Fisher Michal purchased 2,000 shares of CNS Pharmaceuticals, Inc. (CNSP) at $5.00 on 2026-05-18.

Original reporting
SEC EDGAR · Fisher Michal
Published Aug 18, 2026, 1:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 1:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CNSP
Bullish
medium confidence
Mentioned
$CNSP
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNSPBullishLow
01

Why it matters

The filing adds incremental sentiment information but does not include operational updates, guidance, or regulatory/clinical catalysts.

02

Market read

Traders may note the insider buy, but the disclosed dollar value is small and lacks accompanying fundamental news.

03

What to watch

No context is given on prior holdings changes, option exercises, or whether the director’s purchase was part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-08-18, after-hours/near-market open information for traders

Background

This is an SEC Form 4 insider transaction for CNS Pharmaceuticals, Inc., reported as an open-market purchase by a director.

Company-level read

Ticker impact

$CNSPBullishMedium confidence
Context

CNS Pharmaceuticals director Fisher Michal bought 2,000 shares at $5.00/share, totaling $10,000, disclosed via Form 4 filed today.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and small.

Evidence & confidence

The transaction is an insider buy, but the disclosed size is modest ($10k) and there is no 10b5-1 plan, which can increase interpretive noise rather than signal magnitude.

Market effects

No sector-wide read-through is provided beyond a single insider transaction.

None indicated.

None indicated.

Counterpoint

A small open-market buy can reflect routine liquidity needs or diversification rather than a strong conviction signal.

Key entities

  • CNS Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Fisher Michal

    Director who purchased 2,000 shares at $5.00/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $6.1M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 246,568 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $24.85 ($24.69–$24.87, $6.13M total) across 3 trades over 2026-08-13 to 2026-08-17. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Divisadero Street Capital, LLC (10% owner), Divisadero Street Partners, L.P. (10% owner) and Zolezzi William (10% owner).